CClinicalTrials.gg
RecruitingNCT06129591Updated Sep 1, 2026

Topical CBD Scar Healing Study

A Phase 1 interventional study of Vantage Hemp CBD Isolate + Silicone patch and Silicone patch in Paramedian Forehead Flap, sponsored by University of Oklahoma. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by University of Oklahoma · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to find out what effects (good and bad) that cannabidiol (CBD) has on scar healing and appearance in patients who have undergone paramedian forehead flap reconstruction.

Read the detailed description

The patient will be asked to apply a silicone patch to half of the scar and experimental ointment (CBD oil ointment) with silicone patch) to the other half of the scar on their forehead. They will be randomized to which half of the scar the ointment will be applied. Neither they nor their physician will choose which half of the scar will have the experimental ointment applied. Specific instructions will be given to the patient on how to apply each drug (the silicone patch to one segment of the scar and the CBD with silicone patch to the other segment of the scar). They will apply the treatments twice a day for 2 months and, at their follow-up appointments, complete two questionnaires about how the scar is healing. Photographs of the scars will be taken at each visit and will be evaluated to determine if there is an improved outcome in the appearance of the scar.

02

Conditions studied

  • Paramedian Forehead Flap

Keywords

  • CBD oil
  • Paramedian Forehead Flap Reconstruction
  • silicone patch
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients that are adults (18+) of all genders and ethnicities who have undergone a PMFF (Paramedian forehead flap) will be considered for this study.
  • English-speaking patients

Exclusion criteria

Exclusion Criteria

  • Patients younger than 18 years of age
  • Non-English speaking patients
  • Patients with known allergies to CBD
  • Pregnant women
  • Prisoners
  • Patients with moderate to severe hepatic impairment
  • A history of suicidal ideation and behavior within the last 6 months
  • Patients with severe depression
  • Who anticipate coadministration of other CNS depressants including alcohol that could potentiate the sedating effects of the drug
  • Patients with a history of severe hypersensitivity reactions to adhesives
  • Patients who anticipate coadministration of potentially hepatotoxic drugs
  • Patients who anticipate coadministration of sensitive CYP2C19 substrates per labeling

Termination criteria

  • There will be immediate termination from the study if any allergic response to the CBD/silicone combination occurs or if the topical application of CBD/silicone significantly worsens the scar outcome at the Follow Up 2 visit or at any subsequent visit.
  • Subject will not receive any additional CBD doses if they experience an adverse event assessed as ≥ Grade 3 (including hepatotoxicities and hematologic adverse events, ≥ Grade 2 for the system-organ class of Cardiac Disorders) according to CTCAE v5. They will remain on study in follow-up until the adverse event resolves or stabilizes.
  • If the patient voluntarily requests cessation in the study.
  • Pregnancy
  • Increase in serum transaminases (ALT/AST) to above three times the upper limit of normal or increase in total bilirubin to above two times the upper limit of normal.
  • If a subject experiences worsening depression or suicidal ideation or behavior, the participant will be discontinued from treatment with CBD and immediately referred to a mental health professional. The decision to resume treatment with CBD will be made in collaboration with a mental health professional.
04

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Split-scar randomized trial arm with CBD oil

    The study targets the vertical forehead scar, treating half with CBD oil and a silicone patch (experimental).

    Drug: Vantage Hemp CBD Isolate + Silicone patch

  • Placebo comparator
    Split-scar randomized trial arm without CBD oil

    The study targets the vertical forehead scar, treating the other scar half with a silicone patch (control).

    Drug: Silicone patch

Interventions

  • DrugVantage Hemp CBD Isolate + Silicone patch

    The study intervention is prospective in nature. This "split scar" study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale.

  • DrugSilicone patch

    Standard of care silicone patch will be used as the control part of the split scar study. This "split scar" study directly compares two parts of the healing scar during clinic visits. Photos will be taken at each visit to track progress. Assessments will be done over a period of around 7 months using the Modified Patient and Observer Scar Assessment Scale, followed by blinded photo evaluations using the Scar Cosmesis and Rating Scale.

05

What researchers measure

Primary outcomes

  1. Assessment of subjective and objective effects of CBD on the outcomes of healing scars.

    Proportion of patients who have a positive effect using CBD oil in combination with the silicone patch. This will be assessed using the Scar Cosmesis Assessment and Rating (SCAR) scale to determine the impact of CBD oil and silicon patch combo. This photographic evaluation of scare will be done over a period of around 7 months to evaluate the scar outcomes, using the scoring system with minimum score of 0 (being best possible outcome) and maximum score of 13 (worst possible scar outcome).

    Time frame: 2 years

06

Study locations

1 of 1 sites recruiting
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    • Mark Mims, M.D., Ph.D., · Contact · Mark-Mims@ouhsc.edu · 405-271-5504
    • Mark Mims, M.D., Ph.D., · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06129591
Lead sponsor
University of Oklahoma
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Sep 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Ingrid Block
Contact
SCC-IIT-Office@ouhsc.edu
405-271-8777
Lead Nurse
Contact
SCC-IIT-Office@ouhsc.edu
405-271-8777
Mark Mims, M.D., Ph.D.
principal investigator · University of Oklahoma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion